Drug having regulatory cell ligand contained in liposome

Abstract

A liposome containing a regulatory cell ligand such as α-galactosyl ceramide or β-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.

1 . A drug comprising a liposome containing a regulatory cell ligand, as an active ingredient.  
   
   
       2 . The drugs according to  claim 1  wherein the regulatory cell is an NKT cell.  
   
   
       3 . The drugs according to  claim 1  wherein the regulatory cell ligand is β-galactosyl ceramide substances.  
   
   
       4 . The drugs according to  claim 1  wherein the regulatory cell ligand is α-galactosyl ceramide substances.  
   
   
       5 . The drugs according to  claim 1  wherein said liposome further contains CpG oligonucleotide or imiquimod.  
   
   
       6 . The drugs according to  claim 1  wherein said liposome further contains one or more selected from the group consisting of allergens, autoantigens and derivatives thereof, which derivatives are antigens having one or more T cell epitopes.  
   
   
       7 . The drugs according to  claim 1  which is a preventive agent or a therapeutic agent for immune diseases.  
   
   
       8 . The drugs according to  claim 7  wherein the immune diseases are allergic diseases.  
   
   
       9 . The drugs according to  claim 8  wherein the allergic diseases are atopic bronchial asthma, allergic rhinitis, pollinosis or atopic dermatitis.  
   
   
       10 . The drug according to  claim 4  which is a preventive agent or a therapeutic agent for autoimmune diseases or graft-versus-host disease.  
   
   
       11 . A regulatory cell-inducing agent comprising a liposome containing a regulatory cell ligand, as an active ingredient.  
   
   
       12 . The drug according to  claim 2  wherein the regulatory cell ligand comprises a β-galactosyl ceramide substance.  
   
   
       13 . The drug according to  claim 2  wherein the regulatory cell ligand comprises an α-galactosyl ceramide substance.  
   
   
       14 . The drug according to  claim 12  wherein said liposome further contains CpG oligonucleotide or imiquimod.  
   
   
       15 . The drug according to  claim 13  wherein said liposome further contains CpG oligonucleotide or imiquimod.